Agios制药(AGIO)

当期报告

Agios制药(AGIO)2022-11-03 19:06

$Agios制药(AGIO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001439222-22-000098 Act: 34 Size: 349 KB 网页链接

超过5%股东持股披露「修订」

Agios制药(AGIO)2022-10-06 20:42

$Agios制药(AGIO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000019617-22-000474 Act: 34 Size: 89 KB 网页链接

nomage2022-07-28 09:51

$EQRx(EQRX)$ 还是一句话，舒格利单抗是EQrx价值的四分之三，已知EQrx目前估值25.5亿美金（年底也许估值50-100亿美金），求基石应该估值多少？另外基石三个小分子，两个是盖伦奖前100水平。第三个IDH1 $Agios制药(AGIO)$ 昨天突飞猛进，因为后续IDH1也将大放异彩。$基石药业-B(02616)$

First-in-Class靶点DH1抑制剂国内上市

Biotech笔记2022-02-10 13:25

2月9日CDE批准了基石药业的拓舒沃®，成为国内首个以及唯一获批的IDH1抑制剂用于治疗AML(急性髓细胞性白血病)。此前在2021年8月25日，美国FDA批准Ivosidenib 用于既往治疗过的、局部晚期或转移性胆管癌患者，该患者经fda批准的检测检测到异柠檬酸脱氢酶-1 (IDH1)突变。 此前，FDA还批准...

chuminhua2022-02-18 12:43

2月17日，FDA 批准 Agios Pharmaceuticals $Agios制药(AGIO)$ 的 Pyrukynd (mitapivat) 用于治疗患有丙酮酸激酶 (PK) 缺乏症的成人溶血性贫血，无论输血状态如何。该公司指出，其口服 PK 激活剂是首个获批的改善该罕见血液疾病的疗法。
该文件于去年获得 FDA 的优先审查，是基于两项 III 期试...

持股变动年度报告

Agios制药(AGIO)02-04 05:12

$Agios制药(AGIO)$ 5 Annual statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000012 Size: 4 KB 网页链接

超过5%股东持股披露「修订」

Agios制药(AGIO)02-07 03:48

$Agios制药(AGIO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000846087-23-000066 Act: 34 Size: 37 KB 网页链接

持股变动声明

Agios制药(AGIO)02-02 05:12

$Agios制药(AGIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000010 Size: 13 KB 网页链接

超过5%股东持股披露「修订」

Agios制药(AGIO)01-25 23:42

$Agios制药(AGIO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001306550-23-003493 Act: 34 Size: 13 KB 网页链接

持股变动声明

Agios制药(AGIO)01-20 05:06

$Agios制药(AGIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000008 Size: 13 KB 网页链接

超过5%股东持股披露「修订」

Agios制药(AGIO)02-07 03:48

$Agios制药(AGIO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000846087-23-000066 Act: 34 Size: 37 KB 网页链接查看全文

持股变动年度报告

Agios制药(AGIO)02-04 05:12

$Agios制药(AGIO)$ 5 Annual statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000012 Size: 4 KB 网页链接查看全文

持股变动声明

Agios制药(AGIO)02-02 05:12

$Agios制药(AGIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000010 Size: 13 KB 网页链接查看全文

超过5%股东持股披露「修订」

Agios制药(AGIO)01-25 23:42

$Agios制药(AGIO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001306550-23-003493 Act: 34 Size: 13 KB 网页链接查看全文

持股变动声明

Agios制药(AGIO)01-20 05:06

$Agios制药(AGIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000008 Size: 13 KB 网页链接查看全文

持股变动声明

Agios制药(AGIO)01-19 05:18

$Agios制药(AGIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000006 Size: 5 KB 网页链接查看全文

当期报告

Agios制药(AGIO)01-09 20:21

$Agios制药(AGIO)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001193125-23-004143 Act: 34 Size: 13 MB 网页链接查看全文

持股变动声明

Agios制药(AGIO)01-06 05:18

$Agios制药(AGIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000004 Size: 7 KB 网页链接查看全文

首次持股声明

Agios制药(AGIO)01-06 05:12

$Agios制药(AGIO)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001439222-23-000002 Size: 7 KB 网页链接查看全文

员工持股计划

Agios制药(AGIO)01-04 06:27

$Agios制药(AGIO)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-23-000881 Act: 33 Size: 269 KB 网页链接查看全文

超过5%股东持股披露「修订」

$Agios制药(AGIO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000846087-23-000066 Act: 34 Size: 37 KB 网页链接

持股变动年度报告

$Agios制药(AGIO)$ 5 Annual statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000012 Size: 4 KB 网页链接

持股变动声明

$Agios制药(AGIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000010 Size: 13 KB 网页链接

超过5%股东持股披露「修订」

$Agios制药(AGIO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001306550-23-003493 Act: 34 Size: 13 KB 网页链接

持股变动声明

$Agios制药(AGIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000008 Size: 13 KB 网页链接

持股变动声明

$Agios制药(AGIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000006 Size: 5 KB 网页链接

当期报告

$Agios制药(AGIO)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001193125-23-004143 Act: 34 Size: 13 MB 网页链接

持股变动声明

$Agios制药(AGIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001439222-23-000004 Size: 7 KB 网页链接

首次持股声明

$Agios制药(AGIO)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001439222-23-000002 Size: 7 KB 网页链接

员工持股计划

$Agios制药(AGIO)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-23-000881 Act: 33 Size: 269 KB 网页链接